Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

Fig. 1

Multiplex immunohistochemistry for immune cell markers in HPD, non-HPD PD, and PR/CR group (n = 24) †As explorative setting, some cases with available tissues in HPD, non-HPD PD and PR/CR group. HPD hyperprogressive disease, NK natural killer cells, Non-HPD PD non-HPD progressive disease

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us